Instem full year hangs in the balance

Instem Life Sciences, a software provider to the healthcare industry, said several contracts needed to meet revenue and profit expectations for the year remain pending.

The group, which previously cautioned that research organisations, which make up the bulk of its client base, are being cautious in software investment, has seen its share price plunge 57% in the last 12 months.

In its update on trading for the year ending December 31st 201 Instem added that their clients' ability to contribute to current year results will only be known definitively at the year-end.

Article continues below

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

As a result, Instem now intends to announce its planned trading update in early January.

Shares of Instem fell 2.2% at 08:40 in London.

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.